Lytix Biopharma gets regulatory approval to commence ATLAS IT 05 study in 3 European countries

Lytix Biopharma, a Norwegian immuno-oncology company, announces the regulatory approval from European authorities to commence the ATLAS-IT-05 study in three European countries. ATLAS-IT-05 is a phase II combination study evaluating LTX-315 and pembrolizumab in patients with advanced melanoma. The study was initiated at MD Anderson Cancer Center in 2021 and is currently ongoing in the US. The objective of the study is to document whether LTX-315 in combination with pembrolizumab is effective in inducing responses in patients who have failed prior anti PD 1/PD L1 immune checkpoint therapy. The clinical trial application (CTA) has now been approved according to the European Clinical Trial Regulation, and the national authorities in Spain, France and Norway have commended the CTA for ATLAS-IT-05. The approval will enable the expansion of the site network and clinical impact field for LTX-315, mitigate recruitment challenges and drive enrollment in the ATLAS-IT-05 phase II trial towards completion. The study will be performed at highly recognized sites with intratumoral immunotherapy expertise in the three European countries. It will be led by melanoma experts at each site and follow the same protocol as in the US. The regulatory application in Europe was submitted in Q2 2022 and six leading clinical sites in Europe are expected to open during the 4th quarter of 2022. Efforts to prepare the sites for initiation of the study and recruitment of patients is ongoing with the aim to complete enrollment in the study in early 2023.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!